First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of geriatric oncology"
DOI: 10.1016/j.jgo.2020.06.003
Abstract: BACKGROUND Despite the high morbidity and mortality of metastatic colorectal cancer (mCRC) in older patients, they have been underrepresented in clinical trials and their optimal treatment is yet to be determined. This open-label phase II… read more here.
Keywords: metastatic colorectal; plus capecitabine; months median; treatment ... See more keywords
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2020.1807947
Abstract: ABSTRACT Introduction Several agents are being developed for advanced HER2-positive breast cancer, such as potent tyrosine kinase inhibitors (TKI) targeting ErbB family receptors, novel antibody-drug conjugates, higher affinity anti-HER2 antibodies, among others. Neratinib is an… read more here.
Keywords: plus capecitabine; treatment; her2 positive; breast cancer ... See more keywords
Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-065299
Abstract: Objective Neratinib plus capecitabine (Ner+Cap) were proved to be clinically beneficial as a third-line treatment for women with human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC). The objective of this study was… read more here.
Keywords: third line; cost; plus capecitabine; ner cap ... See more keywords
Abstract P2-15-10: Utidelone plus capecitabine versus capecitabine for heavily pretreated metastatic breast cancer and CIPN: Analysis of a single centre cohort
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-p2-15-10
Abstract: Objective In BG01-1323L trial, Utidelone, a novel genetically engineered epothilone analogue, plus capecitabine showed improved progression-free survival and overall survival in heavily pretreated metastatic breast cancer prior to anthracycline and taxane. Chemotherapy-induced peripheral neurotoxicity (CIPN)… read more here.
Keywords: plus capecitabine; centre; utidelone plus; single centre ... See more keywords
Oxaliplatin plus capecitabine (XELOX) in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy (NEO-CLASSIC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4022
Abstract: 4022Background: This multicenter, open-label study (NEO-CLASSIC) evaluated the efficacy and safety of oxaliplatin and capecitabine (XELOX), plus gastrectomy, in localized resectable gastric cancer.... read more here.
Keywords: xelox perioperative; plus capecitabine; neo classic; capecitabine xelox ... See more keywords
TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps4143
Abstract: TPS4143Background: BTCs are rare and have a poor prognosis. These cancers are often diagnosed at advanced stage with limited treatment options and poor overall survival (OS). Overexpression of epid... read more here.
Keywords: plus capecitabine; treatment; treetopp phase; varlitinib plus ... See more keywords
Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.1001
Abstract: 1001 Background: Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC) in phase 1/2 trials. Methods: This double-blinded, multicentre, randomised phase… read more here.
Keywords: her2 metastatic; metastatic breast; pyrotinib; previously treated ... See more keywords
DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Future oncology"
DOI: 10.2217/fon-2017-0025
Abstract: AIM This single institution Phase II study evaluated drug-eluting beads loaded with irinotecan (DEBIRI) plus capecitabine in pretreated patients with colorectal cancer liver metastases. PATIENTS & METHODS Forty patients with liver-limited or liver-dominant disease, who… read more here.
Keywords: plus capecitabine; colorectal cancer; liver; debiri ... See more keywords
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29090476
Abstract: Background: The overexpression of the human epidermal growth factor receptor-2 (HER2) gene is present in 20~25% of breast cancer (BC) patients, contributing to an inferior prognosis. Recent clinical trials showed that pyrotinib has promising antitumor… read more here.
Keywords: pyrotinib plus; lapatinib plus; cost; versus lapatinib ... See more keywords
A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/jcrt.jcrt_792_19
Abstract: Background: Previous studies have shown that vinorelbine/capecitabine (NX) and docetaxel/capecitabine (TX) chemotherapy has a certain effect in advanced breast cancer. However, there are few clinical studies directly comparing TX and NX regimen chemotherapy, especially in… read more here.
Keywords: advanced breast; cancer; breast cancer; trial ... See more keywords